Lakefront Biotherapeutics | GLPG - Operating Profit


Lakefront Biotherapeutics reported EUR-63.7M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
argenx SE USD 394M 22.86M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Genmab DKK 260M 199M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GRIFOLS EUR 249M 26.38M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Merck EUR 1.05B 572M Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
UCB EUR 1.29B 571M Dec/2025
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026